6 Key Developments Shaping mRNA Therapeutics Beyond COVID-19 Vaccines

The emergency use authorizations and subsequent regulatory approvals of the Pfizer–BioNTech BNT162b2 and Moderna mRNA-1273 SARS-CoV-2 vaccines in 2020 and 2021 validated messenger RNA (mRNA) as a therapeutic platform, but the scientific investment enabling those vaccines predates the COVID-19 pandemic by decades.^1-2 As of a recent pipeline analysis, 244 mRNA vaccine and therapeutic candidates are in development, spanning 23 communicable diseases and 69 non-communicable diseases, including 102 oncology-focused candidates. The majority (93%) of these candidates remain in early-stage clinical development, with 12 having advanced to late-stage trials.³ What follows are 6 developments researchers and manufacturers should understand as the mRNA platform matures into a broad therapeutic modality.

1. Personalized cancer vaccines have reached phase 3

The most advanced non-COVID mRNA program as of mid-2026 is mRNA-4157/V940 (intismeran autogene), an individualized neoantigen-specific cancer immunotherapy developed by Moderna in collaboration with Merck. The agent encodes patient-specific neoantigens identified through tumor sequencing, formulated in lipid nanoparticles (LNPs) and administered in combination with pembrolizumab (Keytruda). Multiple phase 3 trials are ongoing in adjuvant melanoma and adjuvant non-small cell lung cancer (NSCLC), with phase 2 investigations in renal cell carcinoma and bladder cancer.⁴ Approximately three years of follow-up from the phase 2 melanoma trial demonstrated durable relapse-free and distant metastasis-free survival benefits, which supports expansion into a registrational program. Phase 2 data from a single tumor type, although encouraging, does not necessarily establish efficacy across the histological diversity represented in the current trial portfolio.

2. Off-the-shelf mRNA oncology approaches are generating phase 2 data

BioNTech's mRNA oncology pipeline includes both off-the-shelf and individualized approaches. BNT111, an off-the-shelf mRNA cancer immunotherapy encoding four melanoma-associated antigens met the primary endpoint of a phase 2 randomized trial in anti-programmed cell death protein-1 refractory or relapsed advanced melanoma, demonstrating a statistically significant improvement in objective response rate (ORR) combined with cemiplimab.⁵ A phase 3 registration trial (Lipo-MERIT) is underway, with primary data collection anticipated in late 2026.

Separately, autogene cevumeran (BNT122/RO7198457), BioNTech’s individualized neoantigen-specific immunotherapy, is being evaluated in phase 2 trials across pancreatic ductal adenocarcinoma, circulating-tumor DNA-positive colorectal cancer, and muscle-invasive urothelial carcinoma.⁶ A phase 2 trial in first-line advanced melanoma presented at the 2025 ESMO Congress did not meet its primary efficacy endpoint, as reported by the company⁷—a result that illustrates the importance of awaiting registrational data before drawing conclusions about platform-wide clinical value.

3. First non-COVID mRNA approval has opened a new regulatory pathway

Moderna’s mRESVIA (mRNA-1345), an mRNA vaccine for preventing respiratory syncytial virus-associated lower respiratory tract disease in adults aged 60 years and older, received FDA approval in June 2024, which marked the first approved mRNA product indication outside of COVID-19.⁸ Concurrent pediatric phase 2 development is ongoing.

Arcturus Therapeutics advanced its candidate, ARCT-2304 (LUNAR-H5N1), a self-amplifying mRNA (sa-mRNA) vaccine for pandemic H5N1 influenza, into a phase 1 randomized placebo-controlled trial in the United States. FDA fast track designation was granted in April 2025.⁹ In addition, the company’s sa-mRNA COVID-19 vaccine (KOSTAIVE) received regulatory approval in Japan in November 2023, which marked the first approved sa-mRNA product globally and established regulatory precedent for the platform.⁹

4. Rare metabolic disease programs are advancing toward registration

Among the most clinically promising non-oncology programs are rare metabolic disease therapeutics. Moderna’s mRNA-3927 encodes both subunits of the propionyl-coenzyme A carboxylase enzyme for treating propionic acidemia, a rare inherited metabolic disorder associated with significant pediatric morbidity and mortality. The candidate is enrolled in a registrational study with data readout anticipated by end of 2026.⁴ In addition, the company’s mRNA-3705, which targets methylmalonic acidemia was selected for FDA’s START pilot program, with a registrational study expected to begin in 2026.¹⁰ These programs extend the platform away from immune stimulation and toward protein replacement therapy through intracellular mRNA translation, introducing distinct requirements around dosing frequency, durability, and tolerability.

5. LNP manufacturing and cold chain constraints remain critical bottlenecks

The LNP–mRNA delivery system that underpinned COVID-19 vaccine manufacturing was optimized for intramuscular administration and transient protein expression. Most non-vaccine applications require different tissue targeting, pharmacokinetic profiles, and, in several cases, repeated dosing. These requirements introduce formulation and manufacturing challenges that go well beyond pandemic-era infrastructure. Flow rate ratios, temperature control, and ethanol dilution kinetics at laboratory scale do not linearly extrapolate to GMP production systems operating at tens of liters per minute.¹¹

Critical material attributes, particularly the purity profiles of ionizable lipids susceptible to oxidative degradation and aldehyde byproduct formation, become increasingly important at scale.¹² Cold chain dependency remains a constraint on accessibility as conventional mRNA–LNP formulations require storage at −20 °C or below. Lyophilization using piperidine-based ionizable lipids that reduce aldehyde-mediated mRNA degradation represents the most advanced near-term approach to thermostability improvement—though no lyophilized mRNA therapeutic has yet reached regulatory approval for chronic-dosing indications.¹²

6. AI and sa-mRNA technology are accelerating platform innovation

Artificial intelligence (AI) and machine learning are being applied at multiple stages of mRNA drug development. BioNTech and Moderna, for example,each employ computational platforms for neoantigen identification in personalized cancer vaccine programs, with reported reductions in individualized manufacturing turnaround from approximately 9 weeks to under 4 weeks.¹³ AI-guided screening of ionizable lipid candidates accelerates identification of novel lipid chemistries with improved tissue targeting selectivity or reduced immunogenic profiles.¹⁴

Sa-mRNA technology, as deployed in Arcturus Therapeutics’ STARR platform, encodes alphavirus replicase machinery alongside the therapeutic antigen. This mechanism enables intracellular mRNA amplification at administered doses in orders of magnitude lower than conventional non-replicating mRNA.¹⁵ Lower mRNA dose per administration reduces LNP excipient load, potentially improving tolerability and reducing per-dose manufacturing cost. Silicon-glass microfluidic chip architectures have also demonstrated scalable LNP production at throughput rates exceeding 17 L per hour with reproducible particle size distributions across 3 orders of magnitude of scale, which addresses operationally disruptive aspects of current manufacturing.¹⁶

The 2026–2028 period will be particularly informative for the mRNA platform, with phase 3 data readouts anticipated for mRNA-4157 in adjuvant melanoma, BNT111 in advanced melanoma, mRNA-1647 for cytomegalovirus prevention, and mRNA-3927 in propionic acidemia.^4–7 Whether these programs achieve regulatory approval will determine not only the commercial trajectories of their developers, but also the degree to which regulators, payers, and health systemswill beprepared to absorb a new therapeutic modality with distinct pharmacological, manufacturing, and economic characteristics.

References

1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
3. Moschioni M, Siraji RA, Dissard R, et al. mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts. Hum Vaccin Immunother. 2026;22(1):2628424. doi:10.1080/21645515.2026.2628424
4. Moderna. mRNA Pipeline (as of May 1, 2026). Accessed June 9, 2026. https://www.modernatx.com/research/product-pipeline
5. BioNTech. BioNTech announces positive topline phase 2 results for mRNA immunotherapy candidate BNT111 in patients with advanced melanoma. Published July 30, 2024. Accessed June 9, 2026. https://investors.biontech.de
6. BioNTech. BioNTech expands late-stage clinical oncology portfolio with initiation of further phase 2 trial with mRNA-based individualized neoantigen specific immunotherapy in new cancer indication. Published October 19, 2023. Accessed June 9, 2026. https://investors.biontech.de/node/15591/pdf
7. BioNTech. BioNTech announces third quarter 2025 financial results and corporate update. Published November 3, 2025. Accessed June 9, 2026. https://investors.biontech.de/news-releases/news-release-details/biontech-announces-third-quarter-2025-financial-results-and/
8. FDA. FDA roundup: May 31, 2024. Published May 31, 2024. Accessed June 9, 2026. https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024
9. Arcturus Therapeutics Holdings. Arcturus Therapeutics receives US FDA fast track designation for the STARR mRNA vaccine candidate ARCT-2304 for pandemic influenza A Virus H5N1. Published April 10, 2025. Accessed June 9, 2026. https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-receives-us-fda-fast-track-designation-0
10. Moderna. Moderna's investigational therapeutic for methylmalonic acidemia (mRNA-3705) selected by US Food & Drug Administration for START pilot program. Published June 4, 2024. Accessed June 9, 2026. https://feeds.issuerdirect.com/news-release.html?newsid=4732150973762706&symbol=MRNA
11. Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146–157. doi:10.1089/nat.2018.0721
12. Hashiba K, Taguchi M, Sakamoto S, et al. Overcoming thermostability challenges in mRNA–lipid nanoparticle systems with piperidine-based ionizable lipids. Commun Biol. 2024;7(1):556. doi:10.1038/s42003-024-06235-0
13. Magoola M, Niazi SK. Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update. Cancers (Basel). 2025;17(11):1882. doi:10.3390/cancers17111882
14. Raza A, Zhang R, Lu R, Wen J, Wu W. Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery. Nanomedicine (Lond). 2025;20(20):2545-2569. doi:10.1080/17435889.2025.2555507
15. Arcturus Therapeutics Holdings. Arcturus Therapeutics announces first quarter 2025 financial update and pipeline progress. Published May 12, 2025. Accessed June 9, 2026. https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2025-financial
16. Shepherd SJ, Han X, Mukalel AJ, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A. 2023;120(33):e2303567120. doi:10.1073/pnas.2303567120